Search research articles
Contact Us
Filters
Showing results (161-170 of 236) with videos related to
Page
of 24
Sort By:
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
January 23, 2015
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
Katherine Zukotynski, Jeffrey T Yap, Anita Giobbie-Hurder, et al.
Cell Reports
|
April 24, 2024
Batf3<sup>+</sup> DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
Andrea Ziblat, Brendan L Horton, Emily F Higgs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2009
Phase I/II trial of tremelimumab in patients with metastatic melanoma
Luis H Camacho, Scott Antonia, Jeffrey Sosman, et al.
Journal for Immunotherapy of Cancer
|
August 18, 2016
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling, Patrick A Ott, F Stephen Hodi, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 14, 2014
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
Robbert M Spaapen, Michael Y K Leung, Mercedes B Fuertes, et al.
Cancer
|
September 25, 2014
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933
Sylvia M Lee, James Moon, Bruce G Redman, et al.
The Journal of Clinical Investigation
|
August 16, 2016
Lymphatic vessels regulate immune microenvironments in human and murine melanoma
Amanda W Lund, Marek Wagner, Manuel Fankhauser, et al.
Cell Reports
|
August 23, 2018
Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance
Michelle L Miller, Christine M McIntosh, Jason B Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 6, 2017
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L Beatty, Peter J O'Dwyer, Jason Clark, et al.
Experimental Hematology & Oncology
|
January 19, 2018
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
Hongtao Liu, Yuanyuan Zha, Noura Choudhury, et al.
Page
of 24
Search research articles
Search
Showing results (161-170 of 236) with videos related to
Sort By:
Page
of 24
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
January 23, 2015
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
Katherine Zukotynski, Jeffrey T Yap, Anita Giobbie-Hurder, et al.
Cell Reports
|
April 24, 2024
Batf3<sup>+</sup> DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
Andrea Ziblat, Brendan L Horton, Emily F Higgs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2009
Phase I/II trial of tremelimumab in patients with metastatic melanoma
Luis H Camacho, Scott Antonia, Jeffrey Sosman, et al.
Journal for Immunotherapy of Cancer
|
August 18, 2016
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling, Patrick A Ott, F Stephen Hodi, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 14, 2014
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
Robbert M Spaapen, Michael Y K Leung, Mercedes B Fuertes, et al.
Cancer
|
September 25, 2014
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933
Sylvia M Lee, James Moon, Bruce G Redman, et al.
The Journal of Clinical Investigation
|
August 16, 2016
Lymphatic vessels regulate immune microenvironments in human and murine melanoma
Amanda W Lund, Marek Wagner, Manuel Fankhauser, et al.
Cell Reports
|
August 23, 2018
Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance
Michelle L Miller, Christine M McIntosh, Jason B Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 6, 2017
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L Beatty, Peter J O'Dwyer, Jason Clark, et al.
Experimental Hematology & Oncology
|
January 19, 2018
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
Hongtao Liu, Yuanyuan Zha, Noura Choudhury, et al.
Page
of 24